Skip to main content
Erschienen in: Journal of Endocrinological Investigation 4/2024

27.02.2024 | Original Article

HMGN1 down-regulation in the diabetic kidney attenuates tubular cells injury and protects against renal inflammation via suppressing MCP-1 and KIM-1 expression through TLR4

verfasst von: J. Yu, J. Da, F. Yu, J. Yuan, Y. Zha

Erschienen in: Journal of Endocrinological Investigation | Ausgabe 4/2024

Einloggen, um Zugang zu erhalten

Abstract

Background

Renal tubular injury, accompanied by damaging inflammation, has been identified to drive diabetic kidney disease (DKD) toward end-stage renal disease. However, it is unclear how damage-associated molecular patterns (DAMPs) activate innate immunity to mediate tubular epithelial cell (TEC) injury, which in turn causes with subsequent sterile inflammation in diabetic kidneys. High mobility group nucleosome-binding protein 1 (HMGN1) is a novel DAMP that contributes to generating the innate immune response. In this study, we focused on determining whether HMGN1 is involved in DKD progression.

Methods

Streptozotocin (STZ)-induced diabetic mice model was established. Then we downrergulated HMGN1 expression in kidney with or without HMGN1 administration. The renal dysfunction and morphological lesions in the kidneys were evaluated. The expressions of KIM-1, MCP-1, F4/80, CD68, and HMGN1/TLR4 signaling were examined in the renal tissue. In vitro, HK2 cells were exposed in the high glucose with or without HMGN1, and further pre-incubated with TAK242 was applied to elucidate the underlying mechanism.

Results

We demonstrated that HMGN1 was upregulated in the tubular epithelial cells of streptozotocin (STZ)-induced type 1 and type 2 diabetic mouse kidneys compared to controls, while being positively correlated with increased TLR4, KIM-1, and MCP-1. Down-regulation of renal HMGN1 attenuated diabetic kidney injury, decreased the TLR4, KIM-1, and MCP-1 expression levels, and reduced interstitial infiltrating macrophages. However, these phenotypes were reversed after administration of HMGN1. In HK-2 cells, HMGN1 promoted the expression of KIM-1 and MCP-1 via regulating MyD88/NF-κB pathway; inhibition of TLR4 effectively diminished the in vitro response to HMGN1.

Conclusions

Our study provides novel insight into HMGN1 signaling mechanisms that contribute to tubular sterile injury and low-grade inflammation in DKD. The study findings may help to develop new HMGN1-targeted approaches as therapy for immune-mediated kidney damage rather than as an anti-infection treatments.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Sabanayagam C, Chee ML, Banu R, Cheng C-Y, Lim SC, Shyong Tai E, Coffman T, Wong TY (2019) Association of diabetic retinopathy and diabetic kidney disease with all-cause and cardiovascular mortality in a multiethnic Asian population. JAMA Netw Open 2:e191540PubMedPubMedCentralCrossRef Sabanayagam C, Chee ML, Banu R, Cheng C-Y, Lim SC, Shyong Tai E, Coffman T, Wong TY (2019) Association of diabetic retinopathy and diabetic kidney disease with all-cause and cardiovascular mortality in a multiethnic Asian population. JAMA Netw Open 2:e191540PubMedPubMedCentralCrossRef
2.
Zurück zum Zitat Saeedi P, Petersohn I, Salpea P, Malanda B, Karuranga S, Unwin N, Colagiuri S, Guariguata L, Motala AA, Ogurtsova K, Shaw JE, Bright D, Williams R (2019) Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the International Diabetes Federation Diabetes Atlas, 9th edition. Diabetes Res Clin Pract 157:107843PubMedCrossRef Saeedi P, Petersohn I, Salpea P, Malanda B, Karuranga S, Unwin N, Colagiuri S, Guariguata L, Motala AA, Ogurtsova K, Shaw JE, Bright D, Williams R (2019) Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the International Diabetes Federation Diabetes Atlas, 9th edition. Diabetes Res Clin Pract 157:107843PubMedCrossRef
3.
Zurück zum Zitat Samsu N (2021) Diabetic nephropathy: challenges in pathogenesis, diagnosis, and treatment. Biomed Res Int 8:1497449 Samsu N (2021) Diabetic nephropathy: challenges in pathogenesis, diagnosis, and treatment. Biomed Res Int 8:1497449
4.
Zurück zum Zitat Niewczas MA, Pavkov ME, Skupien J, Smiles A, Dom ZI, Wilson JM, Park J, Nair V, Schlafly A, Saulnier P-J, Satake E, Simeone CA, Shah H, Qiu C, Looker HC, Fiorina P, Ware CF, Sun JK, Doria A, Kretzler M, Susztak K, Duffin KL, Nelson RG, Krolewski AS (2019) A signature of circulating inflammatory proteins and development of end-stage renal disease in diabetes. Nat Med 25:805–813PubMedPubMedCentralCrossRef Niewczas MA, Pavkov ME, Skupien J, Smiles A, Dom ZI, Wilson JM, Park J, Nair V, Schlafly A, Saulnier P-J, Satake E, Simeone CA, Shah H, Qiu C, Looker HC, Fiorina P, Ware CF, Sun JK, Doria A, Kretzler M, Susztak K, Duffin KL, Nelson RG, Krolewski AS (2019) A signature of circulating inflammatory proteins and development of end-stage renal disease in diabetes. Nat Med 25:805–813PubMedPubMedCentralCrossRef
6.
Zurück zum Zitat Wang J, Xiang H, Lu Y, Tao W, Guang J (2021) New progress in drugs treatment of diabetic kidney disease. Biomed Pharmacother 141:111918PubMedCrossRef Wang J, Xiang H, Lu Y, Tao W, Guang J (2021) New progress in drugs treatment of diabetic kidney disease. Biomed Pharmacother 141:111918PubMedCrossRef
7.
Zurück zum Zitat Selby NM, Taal MW (2020) An updated overview of diabetic nephropathy: diagnosis, prognosis, treatment goals and latest guidelines. Diabetes Obes Metab 22(Suppl 1):3–15PubMedCrossRef Selby NM, Taal MW (2020) An updated overview of diabetic nephropathy: diagnosis, prognosis, treatment goals and latest guidelines. Diabetes Obes Metab 22(Suppl 1):3–15PubMedCrossRef
8.
Zurück zum Zitat La RE, Fiorina P, Astorri E, Rossetti C, Lucignani G, Fazio F, Giudici D, Castoldi R, Bianchi G, Di CV, Pozza G, Secchi A (2000) Patient survival and cardiovascular events after kidney-pancreas transplantation: comparison with kidney transplantation alone in uremic IDDM patients. Cell Transpl 9(6):929–932CrossRef La RE, Fiorina P, Astorri E, Rossetti C, Lucignani G, Fazio F, Giudici D, Castoldi R, Bianchi G, Di CV, Pozza G, Secchi A (2000) Patient survival and cardiovascular events after kidney-pancreas transplantation: comparison with kidney transplantation alone in uremic IDDM patients. Cell Transpl 9(6):929–932CrossRef
9.
Zurück zum Zitat Lazzaroni E, Ben NM, Loretelli C, Pastore I, Plebani L, Lunati ME, Vallone L, Bolla AM, Rossi A, Montefusco L, Ippolito E, Berra C, D’Addio F, Zuccotti GV, Fiorina P (2021) Anti-diabetic drugs and weight loss in patients with type 2 diabetes. Pharmacol Res 171:105782PubMedCrossRef Lazzaroni E, Ben NM, Loretelli C, Pastore I, Plebani L, Lunati ME, Vallone L, Bolla AM, Rossi A, Montefusco L, Ippolito E, Berra C, D’Addio F, Zuccotti GV, Fiorina P (2021) Anti-diabetic drugs and weight loss in patients with type 2 diabetes. Pharmacol Res 171:105782PubMedCrossRef
10.
Zurück zum Zitat Tang S, Yiu WH (2020) Innate immunity in diabetic kidney disease. Nat Rev Nephrol 16:206–222PubMedCrossRef Tang S, Yiu WH (2020) Innate immunity in diabetic kidney disease. Nat Rev Nephrol 16:206–222PubMedCrossRef
11.
Zurück zum Zitat Ichimura T, Asseldonk EJ, Humphreys BD, Gunaratnam L, Duffield JS, Bonventre JV (2008) Kidney injury molecule-1 is a phosphatidylserine receptor that confers a phagocytic phenotype on epithelial cells. J Clin Investig 118:1657–1668PubMedPubMedCentralCrossRef Ichimura T, Asseldonk EJ, Humphreys BD, Gunaratnam L, Duffield JS, Bonventre JV (2008) Kidney injury molecule-1 is a phosphatidylserine receptor that confers a phagocytic phenotype on epithelial cells. J Clin Investig 118:1657–1668PubMedPubMedCentralCrossRef
12.
Zurück zum Zitat Liu BC, Tang TT, Lv LL, Lan H-Y (2018) Renal tubule injury: a driving force toward chronic kidney disease. Kidney Int 93(3):568–579PubMedCrossRef Liu BC, Tang TT, Lv LL, Lan H-Y (2018) Renal tubule injury: a driving force toward chronic kidney disease. Kidney Int 93(3):568–579PubMedCrossRef
13.
Zurück zum Zitat Panduru NM, Sandholm N, Forsblom C, Saraheimo M, Dahlström EH, Thorn LM, Gordin D, Tolonen N, Wadén J, Harjutsalo V, Bierhaus A, Humpert PM (2015) Kidney injury molecule-1 and the loss of kidney function in diabetic nephropathy: a likely causal link in patients with type 1 diabetes. Diabetes Care 38(6):1130–1137PubMedCrossRef Panduru NM, Sandholm N, Forsblom C, Saraheimo M, Dahlström EH, Thorn LM, Gordin D, Tolonen N, Wadén J, Harjutsalo V, Bierhaus A, Humpert PM (2015) Kidney injury molecule-1 and the loss of kidney function in diabetic nephropathy: a likely causal link in patients with type 1 diabetes. Diabetes Care 38(6):1130–1137PubMedCrossRef
15.
Zurück zum Zitat Zhao X, Chen X, Zhang Y, George J, Cobbs A, Wang G, Li L, Emmett N (2019) Kidney injury molecule-1 is upregulated in renal lipotoxicity and mediates palmitate-induced tubular cell injury and inflammatory response. Int J Mol Sci 20:3406PubMedPubMedCentralCrossRef Zhao X, Chen X, Zhang Y, George J, Cobbs A, Wang G, Li L, Emmett N (2019) Kidney injury molecule-1 is upregulated in renal lipotoxicity and mediates palmitate-induced tubular cell injury and inflammatory response. Int J Mol Sci 20:3406PubMedPubMedCentralCrossRef
16.
Zurück zum Zitat Banba N, Nakamura T, Matsumura M, Kuroda H, Hattori Y, Kasai K (2000) Possible relationship of monocyte chemoattractant protein-1 with diabetic nephropathy. Kidney Int 58:684–690PubMedCrossRef Banba N, Nakamura T, Matsumura M, Kuroda H, Hattori Y, Kasai K (2000) Possible relationship of monocyte chemoattractant protein-1 with diabetic nephropathy. Kidney Int 58:684–690PubMedCrossRef
17.
Zurück zum Zitat Brennan E, Kantharidis P, Cooper ME, Godson C (2021) Pro-resolving lipid mediators: regulators of inflammation, metabolism and kidney function. Nat Rev Nephrol 17:725–739PubMedPubMedCentralCrossRef Brennan E, Kantharidis P, Cooper ME, Godson C (2021) Pro-resolving lipid mediators: regulators of inflammation, metabolism and kidney function. Nat Rev Nephrol 17:725–739PubMedPubMedCentralCrossRef
18.
Zurück zum Zitat Skyler JS, Bakris GL, Bonifacio E, Darsow T, Eckel RH, Groop L, Groop P-H, Handelsman Y, Insel RA, Mathieu C, McElvaine AT, Palmer JP, Pugliese A, Schatz DA, Sosenko JM, Wilding JPH, Ratner RE (2017) Differentiation of diabetes by pathophysiology, natural history, and prognosis. Diabetes 66:241–255PubMedCrossRef Skyler JS, Bakris GL, Bonifacio E, Darsow T, Eckel RH, Groop L, Groop P-H, Handelsman Y, Insel RA, Mathieu C, McElvaine AT, Palmer JP, Pugliese A, Schatz DA, Sosenko JM, Wilding JPH, Ratner RE (2017) Differentiation of diabetes by pathophysiology, natural history, and prognosis. Diabetes 66:241–255PubMedCrossRef
20.
Zurück zum Zitat Perez-Morales RE, Del PM, Valdivielso JM, Pérez-Morales RE, Del Pino MD, Valdivielso JM, Ortiz A, Mora-Fernández C, Navarro-González JF (2019) Inflammation in diabetic kidney disease. Nephron 143:12–16PubMedCrossRef Perez-Morales RE, Del PM, Valdivielso JM, Pérez-Morales RE, Del Pino MD, Valdivielso JM, Ortiz A, Mora-Fernández C, Navarro-González JF (2019) Inflammation in diabetic kidney disease. Nephron 143:12–16PubMedCrossRef
21.
Zurück zum Zitat Tang SCW, Yiu WH (2020) Innate immunity in diabetic kidney disease. Nat Rev Nephrol 16(4):206–222PubMedCrossRef Tang SCW, Yiu WH (2020) Innate immunity in diabetic kidney disease. Nat Rev Nephrol 16(4):206–222PubMedCrossRef
23.
Zurück zum Zitat Zhou ZF, Jiang L, Zhao Q, Yu W, Zhou J, Chen Q-K, Lv J-L (2020) Roles of pattern recognition receptors in diabetic nephropathy. J Zhejiang Univ Sci B 21:192–203PubMedPubMedCentralCrossRef Zhou ZF, Jiang L, Zhao Q, Yu W, Zhou J, Chen Q-K, Lv J-L (2020) Roles of pattern recognition receptors in diabetic nephropathy. J Zhejiang Univ Sci B 21:192–203PubMedPubMedCentralCrossRef
25.
Zurück zum Zitat Gong T, Liu L, Jiang W, Zhou R (2020) DAMP-sensing receptors in sterile inflammation and inflammatory diseases. Nat Rev Immunol 20(2):95–112PubMedCrossRef Gong T, Liu L, Jiang W, Zhou R (2020) DAMP-sensing receptors in sterile inflammation and inflammatory diseases. Nat Rev Immunol 20(2):95–112PubMedCrossRef
26.
Zurück zum Zitat Yang D, Tewary P, de la Rosa G, Wei F, Oppenheim JJ (2010) The alarmin functions of high-mobility group proteins. Biochim Biophys Acta (BBA) Gene Regul Mech 1799:157–163CrossRef Yang D, Tewary P, de la Rosa G, Wei F, Oppenheim JJ (2010) The alarmin functions of high-mobility group proteins. Biochim Biophys Acta (BBA) Gene Regul Mech 1799:157–163CrossRef
27.
Zurück zum Zitat Alam MM, Yang D, Trivett A, Meyer TJ, Oppenheim JJ (2018) HMGN1 and R848 synergistically activate dendritic cells using multiple signaling pathways. Front Immunol 9:2982PubMedPubMedCentralCrossRef Alam MM, Yang D, Trivett A, Meyer TJ, Oppenheim JJ (2018) HMGN1 and R848 synergistically activate dendritic cells using multiple signaling pathways. Front Immunol 9:2982PubMedPubMedCentralCrossRef
28.
Zurück zum Zitat Yang D, Postnikov YV, Li Y, Tewary P, de la Rosa G, Wei F, Klinman D, Gioannini T, Weiss JP, Furusawa T, Bustin M, Oppenheim JJ (2012) High-mobility group nucleosome-binding protein 1 acts as an alarmin and is critical for lipopolysaccharide-induced immune responses. J Exp Med 209:157–171PubMedPubMedCentralCrossRef Yang D, Postnikov YV, Li Y, Tewary P, de la Rosa G, Wei F, Klinman D, Gioannini T, Weiss JP, Furusawa T, Bustin M, Oppenheim JJ (2012) High-mobility group nucleosome-binding protein 1 acts as an alarmin and is critical for lipopolysaccharide-induced immune responses. J Exp Med 209:157–171PubMedPubMedCentralCrossRef
29.
Zurück zum Zitat Yu J, Da J, Dong R, Yi S, Yingjie N, Fuxun Y, Li Z, Yan Z (2018) IGF-1R inhibitor ameliorates diabetic nephropathy with suppressed HMGN1/TLR4 pathway. Endocr Metab Immune Disord Drug Targets 18:241–250PubMedCrossRef Yu J, Da J, Dong R, Yi S, Yingjie N, Fuxun Y, Li Z, Yan Z (2018) IGF-1R inhibitor ameliorates diabetic nephropathy with suppressed HMGN1/TLR4 pathway. Endocr Metab Immune Disord Drug Targets 18:241–250PubMedCrossRef
30.
Zurück zum Zitat Yu J, Dong R, Da J, Li J, Yu F, Zha Y (2019) High-mobility group nucleosome-binding protein 1 mediates renal fibrosis correlating with macrophages accumulation and epithelial-to-mesenchymal transition in diabetic nephropathy mice model. Kidney Blood Press Res 44(3):331–343PubMedCrossRef Yu J, Dong R, Da J, Li J, Yu F, Zha Y (2019) High-mobility group nucleosome-binding protein 1 mediates renal fibrosis correlating with macrophages accumulation and epithelial-to-mesenchymal transition in diabetic nephropathy mice model. Kidney Blood Press Res 44(3):331–343PubMedCrossRef
31.
Zurück zum Zitat Mao Y, Yu J, Da J, Yu F, Zha Y (2023) Acteoside alleviates UUO-induced inflammation and fibrosis by regulating the HMGN1/TLR4/TREM1 signaling pathway. PeerJ 11:e14765PubMedPubMedCentralCrossRef Mao Y, Yu J, Da J, Yu F, Zha Y (2023) Acteoside alleviates UUO-induced inflammation and fibrosis by regulating the HMGN1/TLR4/TREM1 signaling pathway. PeerJ 11:e14765PubMedPubMedCentralCrossRef
32.
Zurück zum Zitat Yang Z, Han Z, Alam MM, Oppenheim JJ (2018) High-mobility group nucleosome binding domain 1 (HMGN1) functions as a Th1-polarizing alarmin. Semin Immunol 38:49–53PubMedCrossRef Yang Z, Han Z, Alam MM, Oppenheim JJ (2018) High-mobility group nucleosome binding domain 1 (HMGN1) functions as a Th1-polarizing alarmin. Semin Immunol 38:49–53PubMedCrossRef
33.
Zurück zum Zitat Arts RJW, Yang D, Joosten LAB, van der Meer JWM, Oppenheim JJ, Netea MG, Cheng S-C (2018) High-mobility group nucleosome-binding protein 1 as endogenous ligand induces innate immune tolerance in a TLR4-sirtuin-1 dependent manner in human blood peripheral mononuclear cells. Front Immunol 9:526PubMedPubMedCentralCrossRef Arts RJW, Yang D, Joosten LAB, van der Meer JWM, Oppenheim JJ, Netea MG, Cheng S-C (2018) High-mobility group nucleosome-binding protein 1 as endogenous ligand induces innate immune tolerance in a TLR4-sirtuin-1 dependent manner in human blood peripheral mononuclear cells. Front Immunol 9:526PubMedPubMedCentralCrossRef
34.
Zurück zum Zitat Leemans JC, Kors L, Anders HJ, Florquin S (2014) Pattern recognition receptors and the inflammasome in kidney disease. Nat Rev Nephrol 10(7):398–414PubMedCrossRef Leemans JC, Kors L, Anders HJ, Florquin S (2014) Pattern recognition receptors and the inflammasome in kidney disease. Nat Rev Nephrol 10(7):398–414PubMedCrossRef
35.
Zurück zum Zitat Anders HJ, Banas B, Schlöndorff D (2004) Signaling danger: toll-like receptors and their potential roles in kidney disease. J Am Soc Nephrol 15(4):854–867PubMedCrossRef Anders HJ, Banas B, Schlöndorff D (2004) Signaling danger: toll-like receptors and their potential roles in kidney disease. J Am Soc Nephrol 15(4):854–867PubMedCrossRef
36.
Zurück zum Zitat Arumugam TV, Okun E, Tang SC, Thundyil JS, Taylor SM, Woodruff TM (2009) Toll-like receptors in ischemia-reperfusion injury. Shock 32(1):4–16PubMedCrossRef Arumugam TV, Okun E, Tang SC, Thundyil JS, Taylor SM, Woodruff TM (2009) Toll-like receptors in ischemia-reperfusion injury. Shock 32(1):4–16PubMedCrossRef
37.
Zurück zum Zitat Lin M, Yiu WH, Wu HJ, Chan LYY, Leung JCK, Au WS, Chan KW, Lai KN, Tang SCW (2012) Toll-like receptor 4 promotes tubular inflammation in diabetic nephropathy. J Am Soc Nephrol 23(1):86–102PubMedCrossRef Lin M, Yiu WH, Wu HJ, Chan LYY, Leung JCK, Au WS, Chan KW, Lai KN, Tang SCW (2012) Toll-like receptor 4 promotes tubular inflammation in diabetic nephropathy. J Am Soc Nephrol 23(1):86–102PubMedCrossRef
38.
Zurück zum Zitat Lin M, Yiu WH, Li RX, Wu HJ, Wong DWL, Chan LYY, Leung JCK, Lai KN, Tang SCW (2013) The TLR4 antagonist CRX-526 protects against advanced diabetic nephropathy. Kidney Int 83(5):887–900PubMedCrossRef Lin M, Yiu WH, Li RX, Wu HJ, Wong DWL, Chan LYY, Leung JCK, Lai KN, Tang SCW (2013) The TLR4 antagonist CRX-526 protects against advanced diabetic nephropathy. Kidney Int 83(5):887–900PubMedCrossRef
39.
Zurück zum Zitat Mudaliar H, Pollock C, Komala MG, Chadban S, Wu H, Panchapakesan U (2013) The role of Toll-like receptor proteins (TLR) 2 and 4 in mediating inflammation in proximal tubules. Am J Physiol Renal Physiol 305(2):F143–F154PubMedCrossRef Mudaliar H, Pollock C, Komala MG, Chadban S, Wu H, Panchapakesan U (2013) The role of Toll-like receptor proteins (TLR) 2 and 4 in mediating inflammation in proximal tubules. Am J Physiol Renal Physiol 305(2):F143–F154PubMedCrossRef
40.
Zurück zum Zitat Campbell MT, Hile KL, Zhang H, Asanuma H, Vanderbrink BA, Rink RR, Meldrum KK (2011) Toll-like receptor 4: a novel signaling pathway during renal fibrogenesis. J Surg Res 168(1):e61–e69PubMedCrossRef Campbell MT, Hile KL, Zhang H, Asanuma H, Vanderbrink BA, Rink RR, Meldrum KK (2011) Toll-like receptor 4: a novel signaling pathway during renal fibrogenesis. J Surg Res 168(1):e61–e69PubMedCrossRef
41.
Zurück zum Zitat Wolfs TG, Buurman WA, van Schadewijk A, de Vries B, Daemen MARC, Hiemstra PS, van’t Veer C (2002) In vivo expression of Toll-like receptor 2 and 4 by renal epithelial cells: IFN-gamma and TNF-alpha mediated up-regulation during inflammation. J Immunol 168(3):1286–1293PubMedCrossRef Wolfs TG, Buurman WA, van Schadewijk A, de Vries B, Daemen MARC, Hiemstra PS, van’t Veer C (2002) In vivo expression of Toll-like receptor 2 and 4 by renal epithelial cells: IFN-gamma and TNF-alpha mediated up-regulation during inflammation. J Immunol 168(3):1286–1293PubMedCrossRef
42.
Zurück zum Zitat Mori Y, Ajay AK, Chang J-H, Mou S, Zhao H, Kishi S, Li J, Brooks CR, Xiao S, Woo H-M, Sabbisetti VS, Palmer SC, Galichon P, Li L, Henderson JM, Kuchroo VK, Hawkins J, Ichimura T, Bonventre JV (2021) KIM-1 mediates fatty acid uptake by renal tubular cells to promote progressive diabetic kidney disease. Cell Metab 33:1042–1061PubMedPubMedCentralCrossRef Mori Y, Ajay AK, Chang J-H, Mou S, Zhao H, Kishi S, Li J, Brooks CR, Xiao S, Woo H-M, Sabbisetti VS, Palmer SC, Galichon P, Li L, Henderson JM, Kuchroo VK, Hawkins J, Ichimura T, Bonventre JV (2021) KIM-1 mediates fatty acid uptake by renal tubular cells to promote progressive diabetic kidney disease. Cell Metab 33:1042–1061PubMedPubMedCentralCrossRef
43.
Zurück zum Zitat Scurt FG, Menne J, Brandt S, Bernhardt A, Mertens PR, Haller H, Chatzikyrkou C (2022) Monocyte chemoattractant protein-1 predicts the development of diabetic nephropathy. Diabetes Metab Res Rev 38:e3497PubMedCrossRef Scurt FG, Menne J, Brandt S, Bernhardt A, Mertens PR, Haller H, Chatzikyrkou C (2022) Monocyte chemoattractant protein-1 predicts the development of diabetic nephropathy. Diabetes Metab Res Rev 38:e3497PubMedCrossRef
44.
Zurück zum Zitat Yiu WH, Lin M, Tang SC (2014) Toll-like receptor activation: from renal inflammation to fibrosis. Kidney Int Suppl 4:20–25CrossRef Yiu WH, Lin M, Tang SC (2014) Toll-like receptor activation: from renal inflammation to fibrosis. Kidney Int Suppl 4:20–25CrossRef
46.
Zurück zum Zitat Tam FW, Sanders JS, George A, Hammad T, Miller C, Dougan T, Cook HT, Kallenberg CG, Gaskin G, Levy JB, Pusey CD (2004) Urinary monocyte chemoattractant protein-1 (MCP-1) is a marker of active renal vasculitis. Nephrol Dial Transpl 19(11):2761–2768. https://doi.org/10.1093/ndt/gfh487. (Epub 2004 Sep 7. PMID: 15353578)CrossRef Tam FW, Sanders JS, George A, Hammad T, Miller C, Dougan T, Cook HT, Kallenberg CG, Gaskin G, Levy JB, Pusey CD (2004) Urinary monocyte chemoattractant protein-1 (MCP-1) is a marker of active renal vasculitis. Nephrol Dial Transpl 19(11):2761–2768. https://​doi.​org/​10.​1093/​ndt/​gfh487. (Epub 2004 Sep 7. PMID: 15353578)CrossRef
47.
Zurück zum Zitat Alicic RZ, Rooney MT, Tuttle KR (2017) Diabetic kidney disease: challenges, progress, and possibilities. Clin J Am Soc Nephrol 12(12):2032–2045PubMedPubMedCentralCrossRef Alicic RZ, Rooney MT, Tuttle KR (2017) Diabetic kidney disease: challenges, progress, and possibilities. Clin J Am Soc Nephrol 12(12):2032–2045PubMedPubMedCentralCrossRef
48.
Zurück zum Zitat Kawamoto T, Li M, Kitazaki T, Iizawa Y, Kimura H (2008) TAK-242 selectively suppresses Toll-like receptor 4-signaling mediated by the intracellular domain. Eur J Pharmacol 584:40–48PubMedCrossRef Kawamoto T, Li M, Kitazaki T, Iizawa Y, Kimura H (2008) TAK-242 selectively suppresses Toll-like receptor 4-signaling mediated by the intracellular domain. Eur J Pharmacol 584:40–48PubMedCrossRef
Metadaten
Titel
HMGN1 down-regulation in the diabetic kidney attenuates tubular cells injury and protects against renal inflammation via suppressing MCP-1 and KIM-1 expression through TLR4
verfasst von
J. Yu
J. Da
F. Yu
J. Yuan
Y. Zha
Publikationsdatum
27.02.2024
Verlag
Springer International Publishing
Erschienen in
Journal of Endocrinological Investigation / Ausgabe 4/2024
Elektronische ISSN: 1720-8386
DOI
https://doi.org/10.1007/s40618-023-02292-0

Weitere Artikel der Ausgabe 4/2024

Journal of Endocrinological Investigation 4/2024 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.